Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-methylisothiourea is a small molecule compound primarily used as a chemical intermediate in the synthesis of guanidine derivatives and various pharmaceuticals. It acts as an inhibitor of inducible nitric oxide synthase (iNOS), thereby reducing the production of nitric oxide in biological systems. This mechanism has made it useful in research settings for studying inflammatory processes and related pathologies. In industry, it serves as an intermediate for synthesizing fungicides (such as dimethomorph), insecticides (such as pyrimidinoxyphos), and pharmaceutical agents including guanethidine salts and hydrocortisone sodium phosphate[8][1]. It is not approved or marketed as a therapeutic drug but is widely used in chemical synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-methylisothiourea.